Author information
1
Gastroenterology & Metabolic Diseases, Cisanello Pisa University Hospital, Pisa, Italy.
2
Department of Medical & Surgical Sciences, Bologna University, Bologna, Italy.
3
Radiology Institute, Cisanello Pisa University Hospital, Pisa, Italy.
4
Gastroenterology, Brotzu Hospital, Cagliari, Italy.
5
Internal Medicine, Messina University, Messina, Italy.
6
Gastroenterology, Modena University, Modena, Italy.
7
Gastroenterology, Palermo University, DIBIMIS, Palermo, Italy.
8
General Surgery, Cisanello Pisa University Hospital, Pisa, Italy.
9
Gastroenterology, Cisanello Pisa University Hospital, Pisa, Italy.
Abstract
AIM:
This multicenter field-practice study evaluates outcomes of long-term sorafenib in hepatocellular carcinoma (HCC) patients.
METHODS:
Consecutive HCC patients on sorafenib were enrolled. We evaluated those receiving sorafenib for ≥12 months.
RESULTS:
Out of 800 patients on sorafenib, 81 (10%) received long-term treatment. Median duration of treatment was 22.7 months (range: 12.3-92.6). Only 21 (26%) reported grade 3/4 adverse events. Complete response was reported in 11 patients (14%). Median overall survival was 34.8 months (95% CI: 29.9-44.3). Only baseline Child-Pugh class was associated with survival.
CONCLUSION:
Sorafenib could result in long-term control of HCC in a relevant proportion of patients. Given the availability of regorafenib in the second-line setting, an earlier introduction of systemic therapy may be considered according to clinical indications.